AU2002336532A1 - Linked biaryl compounds - Google Patents

Linked biaryl compounds

Info

Publication number
AU2002336532A1
AU2002336532A1 AU2002336532A AU2002336532A AU2002336532A1 AU 2002336532 A1 AU2002336532 A1 AU 2002336532A1 AU 2002336532 A AU2002336532 A AU 2002336532A AU 2002336532 A AU2002336532 A AU 2002336532A AU 2002336532 A1 AU2002336532 A1 AU 2002336532A1
Authority
AU
Australia
Prior art keywords
biaryl compounds
linked biaryl
linked
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002336532A
Other versions
AU2002336532C1 (en
AU2002336532B2 (en
Inventor
Hiroyuki Abe
Jonathan Houze
Hisashi Kawasaki
Frank Kayser
Rajiv Sharma
Samuel Sperry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Amgen Inc
Original Assignee
Amgen, Inc
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US32255601P priority Critical
Priority to US60/322,556 priority
Priority to US33543401P priority
Priority to US60/335,434 priority
Priority to US37862702P priority
Priority to US60/378,627 priority
Priority to US60/386,833 priority
Priority to US38683302P priority
Priority to PCT/US2002/029232 priority patent/WO2003024395A2/en
Application filed by Amgen, Inc, Japan Tobacco, Inc. filed Critical Amgen, Inc
Publication of AU2002336532A1 publication Critical patent/AU2002336532A1/en
Assigned to AMGEN, INC, JAPAN TOBACCO, INC. reassignment AMGEN, INC Request for Assignment Assignors: JAPAN TOBACCO, INC., TULARIK INC.
Application granted granted Critical
Publication of AU2002336532B2 publication Critical patent/AU2002336532B2/en
Publication of AU2002336532C1 publication Critical patent/AU2002336532C1/en
Application status is Ceased legal-status Critical
Anticipated expiration legal-status Critical

Links

AU2002336532A 2001-09-14 2002-09-13 Linked biaryl compounds Ceased AU2002336532C1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US32255601P true 2001-09-14 2001-09-14
US60/322,556 2001-09-14
US33543401P true 2001-11-30 2001-11-30
US60/335,434 2001-11-30
US37862702P true 2002-05-07 2002-05-07
US60/378,627 2002-05-07
US38683302P true 2002-06-06 2002-06-06
US60/386,833 2002-06-06
PCT/US2002/029232 WO2003024395A2 (en) 2001-09-14 2002-09-13 Linked biaryl compounds

Publications (3)

Publication Number Publication Date
AU2002336532A1 true AU2002336532A1 (en) 2003-06-05
AU2002336532B2 AU2002336532B2 (en) 2007-10-18
AU2002336532C1 AU2002336532C1 (en) 2008-10-16

Family

ID=27502245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002336532A Ceased AU2002336532C1 (en) 2001-09-14 2002-09-13 Linked biaryl compounds

Country Status (13)

Country Link
US (2) US6869975B2 (en)
EP (1) EP1435946B8 (en)
JP (1) JP4269052B2 (en)
KR (1) KR20040063897A (en)
CN (1) CN1585638A (en)
AU (1) AU2002336532C1 (en)
BR (1) BR0212512A (en)
CA (1) CA2460313C (en)
ES (1) ES2443642T3 (en)
IL (1) IL160845D0 (en)
MX (1) MXPA04002330A (en)
NZ (1) NZ531917A (en)
WO (1) WO2003024395A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
IL160845D0 (en) * 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JPWO2005012221A1 (en) * 2003-08-04 2006-09-14 小野薬品工業株式会社 Diphenyl ether compound, its production method and use
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
ES2347578T3 (en) * 2004-05-05 2010-11-02 High Point Pharmaceuticals, Llc Derivatives of the phenoxyacetic acid as ppar agonists.
DE602005024384D1 (en) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc New compounds, its manufacture and use
EP1745014B1 (en) * 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
AU2005272786B2 (en) * 2004-08-12 2011-12-22 Amgen Inc. Bisaryl-sulfonamides
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
AU2005311826A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
AU2005311925A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR PPAR active compounds
FR2880886B1 (en) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si 6-phenylhex-5-enoic acid derivatives, processes for their preparation, pharmaceutical compositions containing same, and therapeutic applications
JP2008527007A (en) 2005-01-14 2008-07-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッドMillennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives having Raf-kinase inhibitory activity
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102005020230A1 (en) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Use of indoline-phenylsulfonamide derivatives
DE102005020229A1 (en) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Use of indoline-phenylsulfonamide derivatives
WO2006132928A2 (en) * 2005-06-03 2006-12-14 Case Western Reserve University Methods and compositions for treating inflammation
ES2372617T3 (en) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc phenoxyacetic acids as activators of PPAR-delta.
US20090054435A1 (en) * 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
NZ567162A (en) * 2005-09-07 2011-06-30 Plexxikon Inc 1, 3-disubstituted indole derivatives for use as PPAR modulators
KR20080042170A (en) * 2005-09-07 2008-05-14 플렉시콘, 인코퍼레이티드 Ppar active compounds
CA2621275A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
SI1976828T1 (en) 2005-12-29 2017-07-31 Celtaxsys, Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
JP2009529512A (en) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー Novel compounds, methods for their production and use
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
PE20090159A1 (en) * 2007-03-08 2009-02-21 Plexxikon Inc Compounds derived from indole-propionic acid as PPAR Modulators
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
CA2758424C (en) 2008-04-21 2018-03-06 Signum Biosciences, Inc. Tryptamine derivatives as pp2a methylation modulators
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
KR20120115989A (en) * 2010-01-06 2012-10-19 판미라 파마슈티칼스, 엘엘씨 Dp2 antagonist and uses thereof
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR20150075120A (en) 2011-02-25 2015-07-02 머크 샤프 앤드 돔 코포레이션 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
BR112015002080A2 (en) 2012-08-02 2017-07-04 Merck Sharp & Dohme compound, pharmaceutical composition, use of a compound, and method of treating or preventing a disorder, condition or disease
WO2014164658A1 (en) 2013-03-12 2014-10-09 Celtaxsys, Inc. Methods of inhibiting leukotriene a4 hydrolase
JP2016513681A (en) 2013-03-14 2016-05-16 セルタクシス,インコーポレイテッド Inhibitor of leukotriene A4 hydrolase
BR112015022864A2 (en) 2013-03-14 2017-07-18 Celtaxsys Inc leukotriene a4 hydrolase inhibitors
JP6562898B2 (en) 2013-03-14 2019-08-21 セルタクシス,インコーポレイテッド Inhibitor of leukotriene A4 hydrolase
US9487493B2 (en) 2013-09-09 2016-11-08 Vtv Therapeutics Llc Use of a PPAR-delta agonist for treating muscle atrophy

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038934A (en) * 1959-03-17 1962-06-12 Smith Kline French Lab Iodinated 4-(4'-alkoxyphenoxy)phenylpropionic acids
US4443536A (en) * 1981-08-25 1984-04-17 Eastman Kodak Company Nondiffusible photographic couplers and photographic elements and processes employing same
US4466902A (en) * 1982-01-31 1984-08-21 Ipposha Oil Industries, Co., Ltd. Rust inhibitor
DE68923591T2 (en) * 1988-09-14 1996-03-28 Eastman Kodak Co A photographic recording material comprising a magenta coupler and chalcogenazolium.
EP0769052A2 (en) 1994-07-01 1997-04-23 The Salk Institute For Biological Studies Mammalian peroxisome proliferator-activated receptors and uses thereof
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
CA2245524A1 (en) 1996-02-02 1997-08-07 Wei Han Antidiabetic agents
EP0882029B1 (en) 1996-02-02 2003-04-02 MERCK & CO., INC. Heterocyclic derivatives as antidiabetic and antiobesity agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
ES2202582T3 (en) 1996-02-02 2004-04-01 MERCK & CO., INC. antidiabetic agents.
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
AU726239B2 (en) * 1997-03-27 2000-11-02 Taisho Pharmaceutical Co., Ltd. 2-phenoxyaniline derivatives
DE69840510D1 (en) 1997-07-24 2009-03-12 Astellas Pharma Inc Medical compositions with cholesterol effluent effect
EP1056751A4 (en) 1997-12-23 2003-01-22 Commw Scient Ind Res Org Boronic compounds
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
AT413386T (en) * 1998-01-29 2008-11-15 Amgen Inc Ppar-gamma modulators
ES2230864T3 (en) * 1998-07-24 2005-05-01 Teijin Limited Derivatives of antranilic acid.
JP2003500432A (en) 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター How to treat alopecia using the diphenyl ether derivative
WO2000078312A1 (en) 1999-06-18 2000-12-28 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1192137B1 (en) 1999-06-30 2013-10-23 Amgen Inc. Compounds for the modulation of ppar-gamma activity
DK1206457T3 (en) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa (thia) zolderivater and their use as modulators PPAP'ER
ES2215719T3 (en) 1999-09-08 2004-10-16 Glaxo Group Limited Oxazole PPAR antagonist.
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001354671A (en) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
CZ302982B6 (en) 2000-06-28 2012-02-01 Amgen Inc. 3-Quinolinyl phenyl sulfonamide compound, the compound for use as a medicament and use of the compound when preparing the medicament
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
AU7772301A (en) 2000-08-11 2002-02-25 Nippon Chemiphar Co Ppardelta activators
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024362D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU2002243778A1 (en) 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
AT437853T (en) * 2001-02-14 2009-08-15 Karobio Ab Glucocorticoid receptors modulators
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
JP4157381B2 (en) 2001-03-23 2008-10-01 日本ケミファ株式会社 Activator of peroxisome proliferator-responsive receptor
WO2003018515A2 (en) * 2001-08-24 2003-03-06 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
IL160845D0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
EP1431284B1 (en) * 2001-09-27 2007-11-21 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
EP1471049A4 (en) * 2002-01-30 2006-08-16 Kissei Pharmaceutical Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Similar Documents

Publication Publication Date Title
GB0101577D0 (en) Compounds
AU2002341920A1 (en) Chemical compounds
AU2002311787A1 (en) Translational profiling
AU2002349297A8 (en) Statin-like compounds
GB0124627D0 (en) Novel compounds
GB0117583D0 (en) Novel compounds
HK1071129A1 (en) Novel compounds
GB0125259D0 (en) Novel compounds
IL158142D0 (en) Novel compounds
HK1090292A1 (en) Compounds effecting glukokinase
IL189357D0 (en) Novel compounds
GB0110901D0 (en) Novel Compounds
AU2002363250A1 (en) Pyrazole-amides and-sulfonamides
AU2002337489A1 (en) Inexsufflator
GB0118479D0 (en) Novel compounds
GB0100889D0 (en) Compounds
AU2002360508A1 (en) Substituted hydroxyethylamines
GB0108800D0 (en) Novel compounds
GB0105895D0 (en) Novel compounds
EP1385515A4 (en) Spiropyrazole compounds
AU2002355245A1 (en) Novel compounds
IL160845D0 (en) Linked biaryl compounds
AU2002343483A1 (en) Hydroxypropylamines
GB0108475D0 (en) New compounds
AU2002343482A1 (en) Prolyl-4-hydroxylases